Literature DB >> 19734220

Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide.

David Pozo1, Per Anderson, Elena Gonzalez-Rey.   

Abstract

T regulatory cells (Tregs) are instrumental in the maintenance of immunological tolerance. Although Treg-based immunotherapy proved successful in preclinical autoimmunity and transplantation, factors involved in the generation of human Ag-specific Tregs are poorly known. In this study, we show that treatment of human CD4+CD25- T cells with the cytokine-like vasoactive intestinal peptide (VIP) during in vitro stimulation induces an anergic FoxP3+CD4+CD25(high) T cell subset displaying potent regulatory activities against allospecific effector T cells, irrespective of the presence of naturally occurring Tregs. VIP-tolerant T cells are characterized by incapability to progress to S phase of cell cycle during stimulation with HLA-disparate APCs by negatively affecting the synthesis of cyclins D3 and E, the activation of cyclin-dependent kinases (cdk)2 and cdk4, and the down-regulation of the cdk inhibitor p27(kip1). VIP interaction with the type 1 VIP receptor and subsequent activation of cAMP/protein kinase A pathway play a major role in all these effects. Moreover, VIP-tolerant T cells protect against acute graft-vs-host disease in a mouse model of allogeneic bone marrow transplantation. The infusion of VIP-tolerant T cells together with the graft significantly reduces the clinical signs and mortality rate typical of the graft-vs-host disease. These effects are mediated by impairing allogeneic haplotype-specific responses of donor CD4+ cells in the transplanted animals. Our results suggest that including alloantigen-specific VIP-generated Tregs may be a valuable tool in therapeutic interventions to promote immunotolerance toward allogeneic grafts and to reduce the need of general immunosuppressive drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19734220     DOI: 10.4049/jimmunol.0900400

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Characterization and use of a rabbit-anti-mouse VPAC1 antibody by flow cytometry.

Authors:  Rebecca J Hermann; Travis Van der Steen; Emilie E Vomhof-Dekrey; Sejaa Al-Badrani; Steve B Wanjara; Jarrett J Failing; Jodie S Haring; Glenn P Dorsam
Journal:  J Immunol Methods       Date:  2011-11-04       Impact factor: 2.303

Review 2.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Authors:  Mario Delgado; Doina Ganea
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

3.  Reproductive immunology: a focus on the role of female sex hormones and other gender-related factors.

Authors:  Elena Peeva
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

4.  Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells.

Authors:  Sheri Tinnell Dorsam; Emilie Vomhof-Dekrey; Rebecca J Hermann; Jodie S Haring; Travis Van der Steen; Erich Wilkerson; Goran Boskovic; James Denvir; Yulia Dementieva; Donald Primerano; Glenn Paul Dorsam
Journal:  Mol Immunol       Date:  2010-02-01       Impact factor: 4.407

5.  Pituitary adenylate cyclase-activating peptide receptor 1 mediates anti-inflammatory effects in allergic airway inflammation in mice.

Authors:  H D Lauenstein; D Quarcoo; L Plappert; C Schleh; M Nassimi; C Pilzner; S Rochlitzer; P Brabet; T Welte; H G Hoymann; N Krug; M Müller; E A Lerner; A Braun; D A Groneberg
Journal:  Clin Exp Allergy       Date:  2010-11-09       Impact factor: 5.018

6.  Gene Deletion of VIP Leads to Increased Mortality Associated with Progressive Right Ventricular Hypertrophy.

Authors:  Anthony M Szema; Sayyed A Hamidi
Journal:  J Cardiovasc Dis       Date:  2014-04-01

7.  Vasoactive intestinal peptide signaling axis in human leukemia.

Authors:  Glenn Paul Dorsam; Keith Benton; Jarrett Failing; Sandeep Batra
Journal:  World J Biol Chem       Date:  2011-06-26

Review 8.  Neuropeptides: keeping the balance between pathogen immunity and immune tolerance.

Authors:  Elena Gonzalez-Rey; Doina Ganea; Mario Delgado
Journal:  Curr Opin Pharmacol       Date:  2010-08       Impact factor: 5.547

Review 9.  Immunotherapy with myeloid cells for tolerance induction.

Authors:  Mercedes Rodriguez-García; Peter Boros; Jonathan S Bromberg; Jordi C Ochando
Journal:  Curr Opin Organ Transplant       Date:  2010-08       Impact factor: 2.640

10.  The expression of vasoactive intestinal peptide receptor 1 is negatively modulated by microRNA 525-5p.

Authors:  Elisa Cocco; Fabiana Paladini; Giuseppe Macino; Valerio Fulci; Maria Teresa Fiorillo; Rosa Sorrentino
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.